Hung-Hsueh Chou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hung-Hsueh Chou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chyong-Huey Lai
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou and Chang Gung University College of Medicine, Taoyuan, Taiwan
3 shared publications Ting-Chang Chang
Chang Gung University
3 shared publicationsJi-Hong Hong
Chang Gung University
2 shared publicationsKoon-Kwan Ng
Chang Gung University
2 shared publicationsChia-Lin Hsieh
Department of Obstetrics and Gynecology, Chang-Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan
1 shared publicationChieh-Sheng Tsai
1 shared publication
Latest Publications
- Open Access
- 1 January 2014
- Published by Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy in Journal of Gynecologic Oncology
- Vol. 25 (3) , 172-173
New frontiers in cancer therapy: the 11th International Meeting of the Asian Clinical Oncology Society (ACOS)
- 1 January 2014
- Published by Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy in Journal of Gynecologic Oncology
- Vol. 25 (3) , 172-173
Open AccessNew frontiers in cancer therapy: the 11th International Meeting of the Asian Clinical Oncology Society (ACOS)
- 31 October 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 127 (1) , 259-260
The poorer survival of patients with cervical adenocarcinoma and adenosquamous cell carcinoma compared to those with squamous cell carcinoma might be improved by a different treatment
- 31 October 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 127 (1) , 259-260
The poorer survival of patients with cervical adenocarcinoma and adenosquamous cell carcinoma compared to those with squamous cell carcinoma might be improved by a different treatment
- 10 February 2005
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 32 (6) , 647-652
Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer?
Compared with computed tomography (CT) and magnetic resonance imaging (MRI), positron emission tomography (PET) may have additional value in the assessment of primary and recurrent cervical cancer. However, the degree of tumour uptake of 18F-2-fluoro-2-deoxy-d-glucose (FDG) uptake is sometimes influenced by diabetes mellitus (DM). Therefore, we conducted this prospective study to compare the diagnostic ability of FDG-PET in patients with cervical cancer complicated by DM and those without DM. Patients with untreated locally advanced primary or clinically curable recurrent cervical carcinoma were enrolled. Both FDG-PET and MRI/CT scans were performed within 2 weeks. Patients were categorised into the following groups: hyperglycaemic DM (fasting blood sugar >126 mg/dl), euglycaemic DM and non-DM. The lesions were confirmed histologically or by clinical follow-up. The receiver operating characteristic curve method, with calculation of the area under the curve (AUC), was used to evaluate the discriminative power. From February 2001 to January 2003, 219 patients (75 with primary and 144 with recurrent cervical cancer) were eligible for analysis. Sixteen had hyperglycaemic DM, 12 had euglycaemic DM and 191 were in the non-DM group. The diagnostic power of PET in the hyperglycaemic DM, euglycaemic DM and non-DM groups did not differ significantly with regard to the identification of either metastatic lesions (AUC, 0.967/0.947/0.925, P>0.05) or primary tumours/local recurrence (AUC, 0.950/0.938/0.979, P>0.05). Considering all DM patients, PET showed a significantly higher detection power than MRI/CT scans in respect of metastatic lesions (AUC=0.956 vs 0.824, P=0.012). In comparison with its accuracy in non-DM patients, the accuracy of PET in cervical cancer patients with mild to moderate DM was not significantly reduced.
- 10 February 2005
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 32 (6) , 647-652
Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer?
Compared with computed tomography (CT) and magnetic resonance imaging (MRI), positron emission tomography (PET) may have additional value in the assessment of primary and recurrent cervical cancer. However, the degree of tumour uptake of 18F-2-fluoro-2-deoxy-d-glucose (FDG) uptake is sometimes influenced by diabetes mellitus (DM). Therefore, we conducted this prospective study to compare the diagnostic ability of FDG-PET in patients with cervical cancer complicated by DM and those without DM. Patients with untreated locally advanced primary or clinically curable recurrent cervical carcinoma were enrolled. Both FDG-PET and MRI/CT scans were performed within 2 weeks. Patients were categorised into the following groups: hyperglycaemic DM (fasting blood sugar >126 mg/dl), euglycaemic DM and non-DM. The lesions were confirmed histologically or by clinical follow-up. The receiver operating characteristic curve method, with calculation of the area under the curve (AUC), was used to evaluate the discriminative power. From February 2001 to January 2003, 219 patients (75 with primary and 144 with recurrent cervical cancer) were eligible for analysis. Sixteen had hyperglycaemic DM, 12 had euglycaemic DM and 191 were in the non-DM group. The diagnostic power of PET in the hyperglycaemic DM, euglycaemic DM and non-DM groups did not differ significantly with regard to the identification of either metastatic lesions (AUC, 0.967/0.947/0.925, P>0.05) or primary tumours/local recurrence (AUC, 0.950/0.938/0.979, P>0.05). Considering all DM patients, PET showed a significantly higher detection power than MRI/CT scans in respect of metastatic lesions (AUC=0.956 vs 0.824, P=0.012). In comparison with its accuracy in non-DM patients, the accuracy of PET in cervical cancer patients with mild to moderate DM was not significantly reduced.
- 30 September 2004
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (3) , 854-857
Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review
- 30 September 2004
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (3) , 854-857
Excellent progression-free survival with liposomal doxorubicin for a patient with recurrent ovarian malignant mixed müllerian tumor: case report and literature review
- 1 October 2001
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 51 (2) , 442-448
Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma
- 1 October 2001
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 51 (2) , 442-448
Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma